Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
Quanterix (NASDAQ: QTRX) has unveiled a new dried blood spot (DBS) extraction kit for their Simoa® assay platform at the AD/PD conference in Vienna. The innovative kit aims to revolutionize neurodegenerative disease testing by enabling biomarker measurement from dried blood spots, offering a more cost-effective and less invasive alternative to traditional venous blood draws.
The DBS extraction kit, developed in collaboration with the DROP-AD Project at the University of Gothenburg, includes buffers and sample preparation protocols. Validation studies demonstrated correlation rates of 0.75 to 0.86 between DBS samples and venous samples in simulated CSF testing using Simoa ALZpath p-Tau 217.
The company's Simoa® technology is being featured in over 80 posters and presentations at the conference, highlighting its impact on neurodegenerative disease research. This advancement aims to improve accessibility to biomarker testing, particularly in remote or resource- settings, and expand participation in Alzheimer's research among under-represented populations.
Quanterix (NASDAQ: QTRX) ha presentato un nuovo kit di estrazione di macchie di sangue secco (DBS) per la loro piattaforma di test Simoa® durante la conferenza AD/PD a Vienna. Questo kit innovativo mira a rivoluzionare il test per le malattie neurodegenerative consentendo la misurazione dei biomarcatori da macchie di sangue secco, offrendo un'alternativa più economica e meno invasiva rispetto ai tradizionali prelievi di sangue venoso.
Il kit di estrazione DBS, sviluppato in collaborazione con il Progetto DROP-AD dell'Università di Göteborg, include tamponi e protocolli di preparazione dei campioni. Gli studi di validazione hanno dimostrato tassi di correlazione tra campioni DBS e campioni venosi compresi tra 0,75 e 0,86 in test simulati di CSF utilizzando Simoa ALZpath p-Tau 217.
La tecnologia Simoa® dell'azienda è presente in oltre 80 poster e presentazioni alla conferenza, evidenziando il suo impatto sulla ricerca sulle malattie neurodegenerative. Questo progresso mira a migliorare l'accessibilità ai test dei biomarcatori, in particolare in contesti remoti o con risorse limitate, e ad ampliare la partecipazione alla ricerca sull'Alzheimer tra le popolazioni sottorappresentate.
Quanterix (NASDAQ: QTRX) ha presentado un nuevo kit de extracción de manchas de sangre seca (DBS) para su plataforma de ensayo Simoa® en la conferencia AD/PD en Viena. Este kit innovador tiene como objetivo revolucionar las pruebas de enfermedades neurodegenerativas al permitir la medición de biomarcadores a partir de manchas de sangre seca, ofreciendo una alternativa más rentable y menos invasiva que las extracciones de sangre venosa tradicionales.
El kit de extracción DBS, desarrollado en colaboración con el Proyecto DROP-AD de la Universidad de Gotemburgo, incluye tampones y protocolos de preparación de muestras. Los estudios de validación demostraron tasas de correlación de 0.75 a 0.86 entre muestras DBS y muestras venosas en pruebas simuladas de LCR utilizando Simoa ALZpath p-Tau 217.
La tecnología Simoa® de la empresa se presenta en más de 80 carteles y presentaciones en la conferencia, destacando su impacto en la investigación de enfermedades neurodegenerativas. Este avance tiene como objetivo mejorar el acceso a las pruebas de biomarcadores, particularmente en entornos remotos o con recursos limitados, y ampliar la participación en la investigación del Alzheimer entre poblaciones subrepresentadas.
Quanterix (NASDAQ: QTRX)는 비엔나에서 열린 AD/PD 컨퍼런스에서 Simoa® 분석 플랫폼을 위한 새로운 건조 혈액 점(DBS) 추출 키트를 발표했습니다. 이 혁신적인 키트는 건조 혈액 점으로부터 바이오마커 측정을 가능하게 하여 신경퇴행성 질환 테스트를 혁신하는 것을 목표로 하며, 전통적인 정맥 혈액 채취에 비해 더 비용 효율적이고 덜 침습적인 대안을 제공합니다.
DBS 추출 키트는 예테보리 대학교의 DROP-AD 프로젝트와 협력하여 개발되었으며, 완충액과 샘플 준비 프로토콜을 포함합니다. 검증 연구에서는 Simoa ALZpath p-Tau 217을 사용한 시뮬레이션된 CSF 테스트에서 DBS 샘플과 정맥 샘플 간의 상관 관계가 0.75에서 0.86 사이로 나타났습니다.
회사의 Simoa® 기술은 컨퍼런스에서 80개 이상의 포스터와 발표에 소개되어 신경퇴행성 질환 연구에 미치는 영향을 강조합니다. 이 발전은 특히 원격 지역이나 자원이 제한된 환경에서 바이오마커 테스트의 접근성을 개선하고, 소외된 인구 집단의 알츠하이머 연구 참여를 확대하는 것을 목표로 하고 있습니다.
Quanterix (NASDAQ: QTRX) a dévoilé un nouveau kit d'extraction de taches de sang séché (DBS) pour sa plateforme de test Simoa® lors de la conférence AD/PD à Vienne. Ce kit innovant vise à révolutionner les tests des maladies neurodégénératives en permettant la mesure des biomarqueurs à partir de taches de sang séché, offrant une alternative plus économique et moins invasive aux prélèvements sanguins veineux traditionnels.
Le kit d'extraction DBS, développé en collaboration avec le projet DROP-AD de l'Université de Göteborg, comprend des tampons et des protocoles de préparation d'échantillons. Des études de validation ont démontré des taux de corrélation de 0,75 à 0,86 entre les échantillons DBS et les échantillons veineux lors de tests simulés de LCR utilisant Simoa ALZpath p-Tau 217.
La technologie Simoa® de l'entreprise est présentée dans plus de 80 affiches et présentations lors de la conférence, soulignant son impact sur la recherche sur les maladies neurodégénératives. Cette avancée vise à améliorer l'accès aux tests de biomarqueurs, en particulier dans les contextes éloignés ou à ressources limitées, et à élargir la participation à la recherche sur l'Alzheimer parmi les populations sous-représentées.
Quanterix (NASDAQ: QTRX) hat auf der AD/PD-Konferenz in Wien ein neues Kit zur Extraktion von Trockenblutproben (DBS) für ihre Simoa®-Testplattform vorgestellt. Das innovative Kit zielt darauf ab, die Tests auf neurodegenerative Erkrankungen zu revolutionieren, indem es die Messung von Biomarkern aus Trockenblutproben ermöglicht und eine kostengünstigere und weniger invasive Alternative zu herkömmlichen venösen Blutentnahmen bietet.
Das DBS-Extraktionskit, das in Zusammenarbeit mit dem DROP-AD-Projekt der Universität Göteborg entwickelt wurde, umfasst Puffer und Protokolle zur Probenvorbereitung. Validierungsstudien zeigten Korrelationsraten von 0,75 bis 0,86 zwischen DBS-Proben und venösen Proben in simulierten CSF-Tests mit Simoa ALZpath p-Tau 217.
Die Simoa®-Technologie des Unternehmens wird in über 80 Postern und Präsentationen auf der Konferenz vorgestellt, was ihren Einfluss auf die Forschung zu neurodegenerativen Erkrankungen unterstreicht. Dieser Fortschritt zielt darauf ab, den Zugang zu Biomarker-Tests zu verbessern, insbesondere in abgelegenen oder ressourcenarmen Umgebungen, und die Teilnahme an der Alzheimer-Forschung unter unterrepräsentierten Bevölkerungsgruppen zu erweitern.
- Launch of new DBS extraction kit expands product portfolio in neurodegenerative disease testing
- Strong validation results showing 0.75-0.86 correlation with traditional methods
- Significant presence in scientific community with 80+ research presentations featuring their technology
- Strategic collaboration with University of Gothenburg's DROP-AD Project
- Correlation rates below 0.90 suggest room for improvement in accuracy compared to traditional methods
Insights
Quanterix's new dried blood spot (DBS) extraction kit represents a meaningful innovation in neurodegenerative disease research with potential long-term commercial implications. The technology addresses a significant barrier in Alzheimer's research by enabling more accessible biomarker detection compared to traditional venous blood draws.
The validation data showing correlations of 0.75-0.86 between DBS and venous samples indicates respectable performance that could make this approach viable for widespread research applications. What's particularly noteworthy is how this advancement potentially expands Quanterix's addressable market by facilitating research in remote or resource- settings and improving participation among underrepresented populations.
The strong presence of Quanterix's Simoa platform in over 80 presentations at AD/PD demonstrates significant adoption within the neurodegenerative disease research community, validating their technology's utility. Their collaboration with the University of Gothenburg's DROP-AD Project further strengthens their scientific credibility.
While this remains primarily a research tool rather than a clinical diagnostic product, it represents a strategic enhancement to their core platform with potential to accelerate biomarker research. The long-term value proposition lies in how simplified collection methods could eventually support more diverse clinical trials and ultimately broader clinical applications for neurodegenerative disease diagnostics.
Simoa® technology highlighted in more than 80 posters and oral presentations demonstrating its impact on neurodegenerative disease research
Current Alzheimer’s and neurodegenerative disease tests often require complex sample handling, repeated collections, and offer limited accessibility, particularly in remote or resource-limited settings, due to their reliance on venous blood draws. To address this, Quanterix, leveraging research from its collaboration with the DROP-AD Project at the University of
“Our new dried blood spot (DBS) extraction kit represents a major step forward in making biomarker testing more accessible,” said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. “By simplifying sample collection, DBS has the potential to expand participation in Alzheimer’s research and clinical trials—especially among under-represented populations. This advancement will deepen our ability to understand the disease and its progression across diverse communities.”
Additionally, Quanterix’s Simoa platform will be featured in over 80 posters, presentations, and sessions at AD/PD, demonstrating its significant role in advancing neurodegenerative disease research. For a full list of research available at AD/PD, please visit AD/PD’s event website.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,200 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331774518/en/
Media Contact:
Marissa Klaassen
(978) 488-1854
media@quanterix.com
Investor Relations Contact:
Joshua Young
(508) 846-3327
ir@quanterix.com
Source: Quanterix Corporation
FAQ
What is the new product announced by Quanterix (QTRX) at AD/PD 2024?
How accurate is Quanterix's (QTRX) new DBS extraction kit compared to traditional methods?
How many research presentations feature Quanterix's (QTRX) Simoa technology at AD/PD?
What are the main advantages of Quanterix's (QTRX) new DBS extraction kit?
